Avantax Advisory Services Inc. Has $1.80 Million Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Avantax Advisory Services Inc. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 20.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,227 shares of the medical research company's stock after acquiring an additional 1,744 shares during the period. Avantax Advisory Services Inc.'s holdings in IQVIA were worth $1,803,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in IQV. Sowell Financial Services LLC bought a new stake in shares of IQVIA in the first quarter valued at about $305,000. Mather Group LLC. lifted its holdings in shares of IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in shares of IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock valued at $956,000 after purchasing an additional 1,562 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of IQVIA by 34.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock valued at $2,338,000 after purchasing an additional 3,398 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in IQVIA by 11.6% during the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock worth $958,000 after acquiring an additional 566 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by company insiders.

IQVIA Price Performance

Shares of IQV traded down $3.42 during trading hours on Friday, reaching $182.44. The stock had a trading volume of 1,644,130 shares, compared to its average volume of 2,321,248. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The stock has a market capitalization of $31.01 billion, a PE ratio of 26.40, a PEG ratio of 2.00 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The company's 50-day moving average is $162.11 and its two-hundred day moving average is $169.89.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the prior year, the company earned $2.64 EPS. IQVIA's revenue was up 5.3% compared to the same quarter last year. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on IQV. HSBC lowered IQVIA from a "buy" rating to a "hold" rating and dropped their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. William Blair reiterated an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Mizuho upped their price objective on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. dropped their price objective on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Finally, UBS Group upped their price objective on IQVIA from $185.00 to $225.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Seven research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.